Story perspectives

CRISPR Therapy Offers Hope for Muenke Syndrome in Infants

9/17/2025

42 7

Summary

Story summary

Researchers are developing a CRISPR-based therapy for Muenke Syndrome, collaborating with the FDA and obtaining rare disease designations.
A novel viral vector targets vascular smooth muscle, addressing rapid disease progression in infants.
An improved base editor protein enhances targeting of the ACTA2 mutation, significantly extending survival in mice.
The therapy shows potential in improving brain and aortic health and reducing exercise intolerance in affected mice.
Kleinstiver's team aims to create safer, more precise gene-editing tools for genetic diseases.

1 of 1

Story summary

Researchers are developing a CRISPR-based therapy for Muenke Syndrome, collaborating with the FDA and obtaining rare disease designations.
A novel viral vector targets vascular smooth muscle, addressing rapid disease progression in infants.
An improved base editor protein enhances targeting of the ACTA2 mutation, significantly extending survival in mice.
The therapy shows potential in improving brain and aortic health and reducing exercise intolerance in affected mice.
Kleinstiver's team aims to create safer, more precise gene-editing tools for genetic diseases.